KR100364390B1 - Compositions for the treatment of diabetes - Google Patents
Compositions for the treatment of diabetes Download PDFInfo
- Publication number
- KR100364390B1 KR100364390B1 KR1020000044392A KR20000044392A KR100364390B1 KR 100364390 B1 KR100364390 B1 KR 100364390B1 KR 1020000044392 A KR1020000044392 A KR 1020000044392A KR 20000044392 A KR20000044392 A KR 20000044392A KR 100364390 B1 KR100364390 B1 KR 100364390B1
- Authority
- KR
- South Korea
- Prior art keywords
- diabetes
- composition
- present
- stomach
- blood
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 50
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 11
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 11
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 11
- 235000013976 turmeric Nutrition 0.000 claims abstract description 11
- 240000008042 Zea mays Species 0.000 claims abstract description 10
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 10
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 10
- 235000005822 corn Nutrition 0.000 claims abstract description 10
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 10
- 239000004576 sand Substances 0.000 claims abstract description 6
- 210000002784 stomach Anatomy 0.000 claims description 21
- 235000002639 sodium chloride Nutrition 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 235000017276 Salvia Nutrition 0.000 claims description 4
- 240000007164 Salvia officinalis Species 0.000 claims description 4
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000281247 Ribes rubrum Species 0.000 claims 1
- 235000016911 Ribes sativum Nutrition 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 10
- 235000008434 ginseng Nutrition 0.000 abstract description 10
- 102000004877 Insulin Human genes 0.000 abstract description 7
- 108090001061 Insulin Proteins 0.000 abstract description 7
- 229940125396 insulin Drugs 0.000 abstract description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract description 6
- 235000009508 confectionery Nutrition 0.000 abstract description 6
- 230000002496 gastric effect Effects 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 abstract description 2
- 206010011224 Cough Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 208000007107 Stomach Ulcer Diseases 0.000 abstract 1
- 201000005917 gastric ulcer Diseases 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 30
- 241000700159 Rattus Species 0.000 description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- 239000000843 powder Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 241000208340 Araliaceae Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- KVSNMTUIMXZPLU-UHFFFAOYSA-N D:A-friedo-oleanane Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CCCC2C KVSNMTUIMXZPLU-UHFFFAOYSA-N 0.000 description 3
- JUUHNUPNMCGYDT-UHFFFAOYSA-N Friedelin Natural products CC1CC2C(C)(CCC3(C)C4CC(C)(C)CCC4(C)CCC23C)C5CCC(=O)C(C)C15 JUUHNUPNMCGYDT-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- OFMXGFHWLZPCFL-SVRPQWSVSA-N friedelin Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@@H]1C OFMXGFHWLZPCFL-SVRPQWSVSA-N 0.000 description 3
- MFVJCHSUSSRHRH-UHFFFAOYSA-N friedeline Natural products CC1(C)CCC2(C)CCC3C4(C)CCC5C(C)(C)C(=O)CCC5(C)C4CCC3(C)C2C1 MFVJCHSUSSRHRH-UHFFFAOYSA-N 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 206010009866 Cold sweat Diseases 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000010030 glucose lowering effect Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 244000024671 Brassica kaber Species 0.000 description 1
- 235000014750 Brassica kaber Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000208368 Euonymus alatus Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229910052571 earthenware Inorganic materials 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- -1 if necessary Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 당뇨병 치료용 조성물에 관한 것이다. 구체적으로, 본 발명은 위모, 고과, 지골피, 옥수수수염, 단삼, 백출, 강황, 복령, 택사, 토사자, 단피를 포함하는 당뇨병 치료용 조성물에 관한 것이다.The present invention relates to a composition for treating diabetes. Specifically, the present invention relates to a composition for treating diabetes, including gastric hair, fruit tree, phalanx, corn beard, sweet ginseng, baekrye, turmeric, bokryeong, taeksa, earth and sand, and short skin.
본 발명의 조성물은 당뇨병 예방, 합병증 예방 및 치료효과를 가지며, 특히 간신음허증(肝腎陰虛症), 위음허(胃陰虛), 폐(肺),심(心),기음허증(氣陰虛症)에 탁월한 효과가 있고, 특히 인슐린 비의존형 당뇨병(제2형 당뇨병)에 대하여 치료효과가 뛰어나며, 인슐린 의존형 당뇨병(제1형 당뇨병)에도 상당히 유효한 생약조성물에 관한 것이다.The composition of the present invention has the effect of preventing diabetes, preventing complications and treating them, in particular, hepatic dementia (肝 腎陰虛 症), stomach ulcer (胃 陰虛), lung (肺), heart (heart), cough (氣陰 虛症) The present invention relates to a herbal composition which has an excellent effect on), is particularly effective against insulin-independent diabetes (type 2 diabetes), and is quite effective against insulin-dependent diabetes (type 1 diabetes).
Description
본 발명은 당뇨병 치료용 조성물에 관한 것이다. 구체적으로, 본 발명은 위모, 고과, 지골피, 옥수수수염, 단삼, 백출, 강황, 복령, 택사, 토사자, 단피를 포함하는 당뇨병 치료용 조성물에 관한 것이다.The present invention relates to a composition for treating diabetes. Specifically, the present invention relates to a composition for treating diabetes, including gastric hair, fruit tree, phalanx, corn beard, sweet ginseng, baekrye, turmeric, bokryeong, taeksa, earth and sand, and short skin.
당뇨병은 비전염성 만성질환으로, 췌장의 β세포에서 분비되는 인슐린이 부족하거나 그 기능을 제대로 발휘하지 못하여 체내에서 포도당이 에너지원으로 이용되지 못하고 혈액내에 고농도로 남아 있다가 소변으로 배설되는 질환이다.Diabetes mellitus is a non-infectious chronic disease, in which the insulin secreted from the pancreatic β cells is insufficient or does not function properly, so glucose is not used as an energy source in the body and remains high in blood and excreted in the urine.
당뇨병은 그 발병원인 및 증상의 치료방법에 따라 크게 인슐린 의존형 당뇨병(Insulin dependent diabetes mellitus, IDDM, 제1형 당뇨병)과 인슐린 비의존형 당뇨병(Non-insulin dependent diabetes mellitus, NIDDM, 제2형 당뇨병)으로 분류할 수 있다.Diabetes is largely divided into insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM). Can be classified.
제1형 당뇨병은 유전적 원인, 바이러스 감염 등에 의해 췌장 β세포의 기능이 저하되어 인슐린이 거의 분비되지 않은 상태로서, 주로 10~20대에 갑자기 발병하며, 연소형 당뇨병이라고도 한다.Type 1 diabetes is a condition in which pancreatic β-cells are depleted due to genetic causes, viral infections, etc., and thus little insulin is secreted. It occurs suddenly in the tens to twenties, and is also called juvenile diabetes.
제2형 당뇨병의 경우는 가족력, 비만, 스트레스, 식사의 잘못 또는 인슐린과 길항(拮抗)하는 약물 등에 의해 발병되는 것으로, 40대 이후에 잘 나타나며, 성인형 당뇨병이라고도 한다. 췌장에서의 인슐린 분비는 충분하지만 인슐린 저항성과 포도당 이용율이 정상인과 달라서 고인슐린혈증임에도 불구하고 혈당이 정상화 되지 않는다.Type 2 diabetes is caused by family history, obesity, stress, eating errors or drugs that antagonize with insulin, etc., which appears well after the age of 40, and is also called adult diabetes. Insulin secretion is sufficient in the pancreas, but blood glucose is not normalized despite hyperinsulinemia due to differences in insulin resistance and glucose utilization from normal individuals.
우리나라의 경우 당뇨병 환자의 95% 이상이 제2형 당뇨병 환자이다.In Korea, more than 95% of diabetics are type 2 diabetics.
한방학적으로는 당뇨병을 음허성(陰虛性), 기음양허성(氣陰陽虛性), 음양양허성(陰陽兩虛性)의 세가지 유형으로 크게 분류한다.In oriental medicine, diabetes is classified into three types: Yin-Yu, Yin-Yin and Yin-Yang.
음허성 당뇨병은 대부분 초기 당뇨병으로 급성 당뇨병이라고도 하며, 장기의 크기별로 그 증상이 달리 나타나는데, 특히 "간울(肝鬱)", "위음허(胃陰虛)", "신음허(腎陰虛)", "폐기음허(肺氣陰虛)", "심기허(心氣虛)", "비허(脾虛)", "기허(氣虛)", "혈허(血虛)"등의 증상을 야기한다. 즉 갈증, 발열, 다뇨, 수척해지고 혈당이 높아지는 특징이 있다.Negative diabetes is mostly early diabetes, also called acute diabetes, and its symptoms are different depending on the size of organs. In particular, "sickness," "wimme," and "moan." It causes symptoms such as "acute lung pain", "heart pain", "unchallenged", "gihe", and "blood scar". . That is, thirst, fever, urination, bleeding, and blood sugar are high.
기음양허성 당뇨병은 만성당뇨로 10년 이상된 당뇨병 환자에게서 나타난다. 기와 음이 동시에 허할때 발병하며, 당수치는 높지 않고, 사지가 나른하고, 힘이 없다.Acute diabetes mellitus occurs in diabetic patients 10 years or older with chronic diabetes. It occurs when both Qi and Yin are in vain at the same time, the sugar level is not high, the limb is drowsy, and there is no strength.
음양양허성 당뇨는 노인성 당뇨로 주로 말기환자에게서 나타나며, 기와 음이 동시에 허할때 발병하고, 합병증이 나타난다.Yin-Yang-Yang Diabetes is senile diabetes, mainly in terminal patients.
당뇨를 앓는 주원인은 인슐린 수체 결합력의 영향 때문이다. 인체 자체에는 "특이성 면역기능"과 "비특이성 면역기능"이 있는데, 다년간의 임상실험을 통하여 비특이성 면역력이 상승할 때, 인슐린 수체 결합력이 저하되어 혈당이 높아지는 것으로 입증되었다. 이에 한방에서는 수체 결합력과 비장기능은 서로 상통하는 것이며, 간울, 기허, 혈허, 폐기, 음허, 신음허등은 직접적으로 비장기능에 영향을 미쳐 수체 결합력을 저하시키는 것으로 보고 있다.The main cause of diabetes is the effect of insulin receptor binding. The human body itself has "specific immune function" and "non-specific immune function". Many years of clinical trials have shown that when the non-specific immunity rises, insulin receptor binding capacity is lowered and blood glucose is increased. In oriental medicine, the water-binding force and spleen function are in common with each other, and Gulf, Giheum, Bloodshed, Disposal, Eum-Hee, Moo-Hee-Hu directly affects the spleen function and decreases the water-binding ability.
불치로 알려진 당뇨병도 조기 발견하면 완치가 가능하다. 조기 치료하므로써 합병증을 미리 예방할 수 있기 때문이다.Diabetes, also known as incurable, can be cured if detected early. Early treatment can prevent complications.
당뇨병 조기 발견은 당불내성 상태를 찾아내는 것이다. 당불내성이란 정상인과 당뇨환자의 중간단계로, 당뇨가 본격적으로 시작되기 전의 상태이다. 즉 혈당을 조절하고 인슐린을 분비하는 췌장 베타세포의 기능이 저하 되거나 인슐린 저항성이 있어 포도당을 세포로 운반하는 능력이 저하 된 것을 말한다.Early detection of diabetes is finding a glucose intolerance. Glucose intolerance is an intermediate stage between normal and diabetic patients, before the onset of diabetes. In other words, the ability of the pancreatic beta cells to control blood sugar and secrete insulin is reduced or insulin resistance is reduced, and thus the ability to transport glucose to cells is reduced.
당뇨병 치료가 늦어지면 합병증이 발병하게 되는데, 보통 급성 합병증(당뇨병성 케톤산증, 고삼투성비케톤성 혼수, 젖산증)과 만성 합병증(당뇨병성 망막증, 당뇨병성 신증, 당뇨병성 신경병증)으로 인해 인체의 전반적인 대사기능 및 감각기능이 저하된다.Complications develop later in diabetes treatment, usually due to acute complications (diabetic ketoacidosis, hyperosmotic biketogenic coma, lactic acidosis) and chronic complications (diabetic retinopathy, diabetic nephropathy, diabetic neuropathy). Overall metabolic and sensory functions are reduced.
이러한 당뇨병 및 합병증을 한방으로 치료하기 위해 화살나무(Euonymus alata)에서 성분을 추출해 내어 사용하였다. 화살나무는 일명 위모(衛矛), 귀전우(鬼箭羽), 신전목(神箭木)이라고도 한다.In order to treat these diabetes and complications with herbal medicines, components were extracted from Euonymus alata. Arrow tree is also known as Yumo (귀), ear jeon (鬼 箭 羽), Shinjeonmok (神箭 木).
위모는 원인을 알 수 없는 병, 산후 피멎이 약, 정신불안, 여성의 자궁출혈, 대하, 어혈을 없애는 민간약으로 쓰여왔다. 또 혈액순환을 좋게하고, 어혈을 풀어주며 염증을 없애고 정신을 안정시켜주는 것으로 나타나 있으며, 위암, 식도암등 여러가지 암에도 효과가 있는 것으로 알려져 있다.Stomach hair has been used as a folk medicine that has no known cause, postpartum blood pill, mental anxiety, women's uterine bleeding, treatment, and blood loss. In addition, it improves blood circulation, releases blood, removes inflammation and stabilizes the mind, and is known to be effective in various cancers such as gastric cancer and esophageal cancer.
최근에는 이러한 작용 이외에도 위모 전체에 함유되어 있는 옥살로아세트산의 혈당강하작용이 알려져 당뇨병 치료제로서의 연구가 진행되고 있다.Recently, in addition to such action, the hypoglycemic action of oxaloacetic acid contained in the entire stomach is known, and research as a therapeutic agent for diabetes is being conducted.
위모의 당뇨병 치료작용은 위모에 존재하는 옥살로아세트산(Oxaloacetic acid)이 췌장의 랑겔한스섬(Langerhan's islet)을 증식시켜 β세포에서 만들어지는 인슐린 분비를 촉진하기 때문인 것으로 간주되고 있다. 또한, 위모에 존재하는 프리델린(Friedelin)의 파혈작용에 의하여 콜레스테롤치를 내려줌으로써 간접적으로 당뇨병의 치료효과를 나타낼 수 있다. 그러나 프리델린에 의한 파혈작용이 지나치게 급격하고 강하여 위장에 담비통 증상을 유발하고, 내장을 허하게 만드는 작용이 있어 단일 성분으로는 복용이 불가능하다.The treatment of diabetes in the stomach is thought to be due to the oxaloacetic acid present in the stomach, which promotes the release of β cells from the pancreatic Langerhan's islet. In addition, by lowering the cholesterol level by the shedding action of Friedelin (Friedelin) present in the stomach can indirectly exhibit a therapeutic effect of diabetes. However, the septic action caused by Friedellin is too sharp and strong, causing stomach pain in the stomach, and the intestines have the effect of dissolving, so it is not possible to take a single ingredient.
본 발명은 위모에 고과, 지골피, 옥수수수염, 단삼, 백출, 강황, 복령, 택사, 토사자, 단피를 배합하여 위모의 독성을 완하시키면서, 음허성 당뇨병 즉 제2형 당뇨병에 탁월한 치료 효과를 나타내는 새로운 생약 조성물을 제공하는 것이다.The present invention is a combination of the fruit tree, golgol, corn beard, sweet ginseng, baekchul, turmeric, Bokryeong, Taeksa, Tosa, short skin to relieve the toxicity of the stomach, while showing a novel therapeutic effect on the negative diabetes mellitus type 2 diabetes It is to provide a herbal composition.
본 발명은 당뇨병 치료에 유용한 생약조성물에 관한 것이다. 구체적으로, 본 발명은 위모, 고과, 지골피, 옥수수수염, 단삼, 백출, 강황, 복령, 택사, 토사자, 단피를 포함하는 당뇨병 치료용 생약조성물에 관한 것이다.The present invention relates to a herbal composition useful for treating diabetes. Specifically, the present invention relates to a herbal composition for treating diabetes, including gastric hair, fruit tree, phalanx, corn beard, sweet ginseng, baekrye, turmeric, bokyeong, taeksa, earth and sand, and short skin.
상기한 바와 같이 위모의 옥살로아세트산 성분에 여러가지 생약성분을 배합하여 위모의 단독 사용에 따른 부작용을 방지함은 물론 당뇨병에 의해 야기될 수있는 각종 증상을 모두 적절히 치료할 수 있어 음허성 당뇨병에 효과적으로 사용할 수 있다.As described above, by combining various herbal ingredients with the oxaloacetic acid component of the stomach, it is possible to prevent side effects due to the use of the stomach alone as well as to treat all the various symptoms that can be caused by diabetes. Can be.
이하에서는 본 발명의 조성물에서 각각의 생약성분이 어떠한 작용을 나타냄으로써 당뇨병 치료효과가 나타나는지를 구체적으로 설명하고자 한다.Hereinafter, it will be described in detail how the effect of each herbal ingredient in the composition of the present invention to treat diabetes.
위모(衛矛)는 쓰고 차서 파혈작용과 양혈작용을 한다. 위모속에 있는 프리델린은 파혈작용에 의하여 콜레스테롤치를 내려주고, 옥살로아세트산은 혈당 및 뇨당치를 내려주고 체중을 증가시켜준다.Stomach (衛 矛) to write and sputum acts and bleeding. Friedelin in the stomach lowers cholesterol by blood clotting, and oxaloacetic acid lowers blood sugar and urine glucose and increases weight.
고과(苦瓜)는 도위를 식히고, 열을 조절하며, 해독작용을 하고, 갈증을 억제시킨다.Overgrowth cools the stomach, regulates heat, detoxifies, and suppresses thirst.
지골피(地骨皮)는 허약한 신체와 조열과 식은땀을 치료하고, 열과 혈을 식혀주며, 당을 저하시켜 준다.Phalanges (地骨皮) is to treat the weak body and fever and cold sweat, cool the fever and blood, and lowers sugar.
옥수수수염(玉米須)은 수분을 조절하고, 열을 발산케 하고, 간을 진정시키며, 담낭을 조절해 주고, 당을 저하시켜준다.Corn beard (玉米 須) regulates moisture, releases heat, calms the liver, regulates the gallbladder, and lowers sugar.
단삼(丹參)은 혈액순환과 신경안정을 돕고, 화농을 배출시키고 통증을 억제한다.Danshen (丹 參) helps blood circulation and nerve stabilization, discharges purulent and suppresses pain.
위 다섯가지 약재를 함께 복용하면 열을 조절하고, 해독할 수 있으며, 허약한 신체와 조열과 식은땀을 치료할 수 있으며, 위모의 당 저하 기능을 강화시킨다.Take these five medicines together to control and detox your fever, to treat your fragile body, fever and cold sweats, and to strengthen the sugar-lowering function of your stomach.
백출(白朮)은 지방을 보하고, 조습(燥濕)을 조절하고 중화작용을 한다.Baekchul (白 朮) is a fat, humidity control (燥濕) to control and neutralize.
강황(姜黃)은 비장을 따뜻하게 하고, 중화작용을 하며, 간을 진정시키고, 해독작용을 한다.Turmeric warms the spleen, neutralizes, calms the liver, and detoxifies.
인삼(人參)은 타액을 분비하고 보혈작용을 하며, 원기를 돋우며, 항독, 해독작용을 한다.Ginseng (人 參) secretion of saliva and blood work, energizes, anti-toxic, detoxification.
복령(茯笭)은 심신을 안정시키고 소변을 조절해 준다.Bokryeong stabilizes the mind and body and regulates urine.
택사(澤瀉)는 소변을 조절해 주고, 신경안정과 해독작용을 한다.Taeksa (澤瀉) to regulate the urine, the nerve stability and detoxification.
토사자(兎絲子)는 음양을 조절해 주고, 신장을 보하고 눈을 밝게 한다.Tosa (兎 絲 子) is to control the yin and yang, to show the height and brighten the eyes.
단피(丹皮)는 내열을 내려주고, 약성을 조절해 준다.Short skin (丹皮) lowers the heat, and controls the weakness.
이상 일곱가지 약재를 함께 복용하면, 원기가 왕성해지며 해독작용을 하고, 수분을 조절하고 신경을 안정시켜 주며, 음양을 고르게 하고, 간과 신장을 보할 수 있다.If you take these seven herbs together, you will feel energetic and detoxify, regulate moisture, stabilize your nerves, even out yin and yang, and protect your liver and kidneys.
상기한 바와 같이 본 발명의 조성물에서는 각각의 생약성분의 작용이 조합되어 나타나므로, 사용하는 생약성분 상호간에 양열(凉熱), 한온(寒溫), 독해(毒解) 라는 상대성을 배합시켜 약성을 조화시키는 기능을 수행한다. 그리고, 타액을 분비시켜 갈증을 억제시키고, 기를 보강하고 열을 내려 주며, 당을 저하시키고 간과 신장을 보하여 당뇨병에 대하여 우수한 치료효과를 나타내 준다.As described above, in the composition of the present invention, the action of each herbal ingredient appears in combination, and thus, the herbal ingredients used are formulated by relativity such as heat of fever, cold, and reading. It performs a function that harmonizes. In addition, saliva secretion suppresses thirst, reinforces the group and lowers heat, lowers sugar and protects the liver and kidneys.
본 발명의 조성물에서는 각각의 주생약성분을 중량기준으로 하여 위모:고과:지골피:옥수수수염:단삼:백출:강황:복령:택사:토사자:단피를 30:10:10:10:5:5:5:7:5:5:3의 중량비로 배합하여 사용한다. 이와 같은 조성비는 각각의 생약성분이 갖는 유효용량과 부작용 등을 고려하여 찾아낸 것이며, 그 비율의 범위를 벗어나는 경우에는 효과가 급격히 떨어지거나 부작용의 우려가 있다.In the composition of the present invention, each of the main herbal ingredients is based on the weight of stomach hair: fruit fruit: phalanx skin: corn mustard: salvia: white extract: turmeric: Fuling: Taeksa: earthenware: skin: 30: 10: 10: 10: 5: 5: The weight ratio of 5: 7: 5: 5: 3 is used. Such a composition ratio is found in consideration of the effective dose and side effects of each herbal ingredient, and if it is out of the range of the ratio, there is a possibility that the effect is drastically reduced or side effects.
본 발명에 따르는 조성물의 제조방법은 다음과 같다.The preparation method of the composition according to the present invention is as follows.
위모는 깨끗이 씻은 후, 증류수에 담그고, 수용액을 수산화나트륨으로 ph 9로 맞춘후, 감압하에 3시간 동안 달여 여과시키고, 여과액을 농축하여 침고로 만든후 진공상태에서 건조한 다음, 분쇄하여 100회 이상 체를 쳐 분말상태로 만든다.The stomach is washed thoroughly, immersed in distilled water, the aqueous solution is adjusted to ph 9 with sodium hydroxide, and then filtered by decoction for 3 hours under reduced pressure, the filtrate is concentrated to make a precipitate, dried under vacuum, and then pulverized. Sieve to powder.
옥수수염은 깨끗이 씻어 50℃(효모균 첨가)에서 발효시킨 다음, 잡티를 가려내고 5배의 증류수를 가한 후 감압하에 3시간 동안 달여 여과한 후, 농축시켜 건조한 후, 분쇄하여 100회 이상 체를 쳐 분말상태로 만든다.Corn salts are washed and fermented at 50 ℃ (added with yeast), then the blemishes are screened and 5 times distilled water is added, and the mixture is filtered for 3 hours under reduced pressure, concentrated to dryness, pulverized and sieved at least 100 times. Powder it.
인삼은 깨끗이 씻어 건조한 다음 갈아서 100회 이상 체를 쳐 분말 상태로 만든다. 단삼은 70% 에탄올로 추출한 후, 감압하에 농축하고, 진공상태에서 건조시킨 후, 분쇄하여 100회 이상 체를 쳐 분말상태로 만든다.Ginseng is washed, dried and ground, sieved more than 100 times, and powdered. Salvia ginseng is extracted with 70% ethanol, concentrated under reduced pressure, dried in vacuo, pulverized and sieved at least 100 times to obtain a powder state.
강황, 백출, 지골피, 복령, 단피, 택사, 토사자는 합하여 5배의 증류수를 가한 후 감압하에 3시간 달이고, 감압하에 농축시킨 다음 진공 건조시켜 100회 이상 체를 쳐 분말 상태로 만든다. 고과는 깨끗이 씻어 냉동 추출한 후, 여액을 농축시켜 액체를 얻는다. 이를 여주소라 한다.Turmeric, Baekchul, Jigolpi, Bokryeong, Danpi, Taeksa, Tosa were added 5 times distilled water in total, 3 hours under reduced pressure, concentrated under reduced pressure and dried under vacuum to sieve 100 times to make powder. The fruit is washed, frozen and extracted, and the filtrate is concentrated to obtain a liquid. This is called an address.
이상의 분말상태의 성분들을 혼합하여 100회 이상 체를 치고, 여주소 농축액에 혼합성분가루를 혼합하고, 진공 건조시키면 본 발명의 목적하는 조성물을 얻게 된다.When the above components in powder form are mixed and sieved at least 100 times, the mixed component powder is mixed with the filter concentrate and dried in vacuo to obtain the desired composition of the present invention.
또한 상기 조성물 이외에도 필요에 따라 화분, 복분자, 숙지황, 감초, 오미자, 천궁, 영지, 황기, 맥동, 옥죽, 산약등의 성분을 선택적으로 추가할 수 있다.In addition to the composition, if necessary, components such as pollen, bokbunja, sagejiku, licorice, schisandra, cheongung, ganoderma lucidum, astragalus, pulsation, jade porridge, and caustic may be optionally added.
본 발명의 조성물은 당뇨병의 치료를 위해 임상적으로 이용시 약제학적 분야에서의 통상적인 방법에 따라 경구투여용 제제, 예를들면 환제, 정제, 캡슐제, 액제, 현탁제 등의 제제로 제형화시켜 사용할 수 있다.The composition of the present invention may be formulated into oral preparations, such as pills, tablets, capsules, solutions, suspensions, and the like, according to conventional methods in the pharmaceutical field when used clinically for the treatment of diabetes. Can be used.
당뇨병의 치료를 위한 본 발명의 조성물의 투여용량은 환자의 성별, 연령, 건강상태, 치료할 당뇨병의 종류, 중증도, 합병증 등에 따라 적절히 선택할 수 있으나, 일반적으로 성인(체중 약 50㎏)에 대한 1일 용량은 3~8g, 바람직하게는 4~5g이다.The dosage of the composition of the present invention for the treatment of diabetes mellitus may be appropriately selected depending on the sex, age, health condition, type of diabetes mellitus to be treated, severity, complications, etc., but is generally 1 day for an adult (weight about 50 kg). The capacity is 3 to 8 g, preferably 4 to 5 g.
또한 본 발명의 조성물은 많은 양에서도 독성이 없으므로 혈당강하용 건강식품으로 사용될 수 있다. 식품으로 사용할 때에는 상기 조성으로 이루어진 분말을 통상적인 식음료 제조방법에 따라 제조하여 사용한다.In addition, since the composition of the present invention is not toxic in a large amount, it can be used as a health food for lowering blood sugar. When used as a food, the powder consisting of the composition is prepared and used according to the conventional food and beverage manufacturing method.
본 발명은 이하의 실시예 및 실험예에 의해 더욱 구체적으로 설명되나, 본 발명이 이들에 의해 제한되는 것은 아니다.The present invention is described in more detail by the following examples and experimental examples, but the present invention is not limited thereto.
실시예 1Example 1
위모 300g을 깨끗이 씻어 건조한 후, 증류수에 담그고, 수용액을 수산화나트륨으로 ph 9로 맞춘후, 감압하에 3시간 동안 달여 여과시키고, 여과액을 농축하여 침고로 만든후 진공상태에서 건조한 다음, 분쇄하여 100회 이상 체를 쳐 분말상태로 만든다(1). 옥수수염 100g을 깨끗이 씻어 50℃(효모균 첨가)에서 발효시킨 다음, 잡티를 가려내고 5배의 증류수를 가한 후 감압하에 3시간 동안 달여 여과한 후, 농축시켜 건조한 후, 분쇄하여 100회 이상 체를 쳐 분말상태로 만든다(2). 인삼 50g을 깨끗이 씻어 건조한 다음 갈아서 100회 이상 체를 쳐 분말 상태로 만든다(3). 단삼 50g을 70% 에탄올을 이용하여 추출한 후, 감압하에 농축하고, 진공상태에서 건조시킨 후, 분쇄하여 100회 이상 체를 쳐 분말상태로 만든다(4). 강황, 백출, 지골피, 복령, 단피, 택사, 토사자는 합하여 5배의 증류수를 가한 후 감압하에 3시간 달이고, 감압하에 농축시킨 다음 진공 건조시켜 100회 이상 체를 쳐 분말 상태로 만든다(5).After washing and drying 300g of the stomach hair, immersed in distilled water, and the aqueous solution was adjusted to ph 9 with sodium hydroxide, and then filtered under reduced pressure for 3 hours, filtered and the filtrate was concentrated to make a precipitate, dried under vacuum, and then pulverized 100 Sieve at least twice to form powder (1). 100 g of corn salt was washed and fermented at 50 ° C. (added with yeast), then the blemishes were removed, 5 times distilled water was added, and the mixture was filtered for 3 hours under reduced pressure, concentrated to dryness, and pulverized. To form powder (2). Wash 50g of ginseng, dry it, grind it and sift it over 100 times to make it powder (3). After extracting 50g of salvia using 70% ethanol, concentrated under reduced pressure, dried in vacuo, pulverized and sieved 100 times to make a powder (4). Turmeric, Baekchul, Jigolpi, Bokryeong, Danpi, Taeksa, Tosa are combined with 5 times distilled water, and then depressurized for 3 hours, concentrated under reduced pressure, and dried under vacuum to sieve 100 times to form a powder (5).
고과 100g을 깨끗이 씻어 냉동 추출한 후, 여액을 농축시켜 액체를 얻는다(6). 수득된 (1)(2)(3)(4)(5)를 혼합하여 100회 이상 체를 치고, (6)용액에 혼합하여 진공 건조시킨다.After washing 100 g of confectionery and freezing, the filtrate is concentrated to obtain a liquid (6). The obtained (1) (2) (3) (4) (5) is mixed and sieved at least 100 times, (6) is mixed with the solution and dried in vacuo.
최종 생성된 생약 조성물의 구성비는 다음과 같다. 위모(30%), 인삼(5%), 강황(5%), 고과(10%), 옥수수염(10%), 단삼(5%), 백출(5%), 지골피(10%), 복령(7%), 단피(3%), 택사(5%), 토사자(5%)로 구성되어 진다.The composition ratio of the final herbal composition is as follows. Stomach (30%), ginseng (5%), turmeric (5%), fruit (10%), corn salt (10%), sweet ginseng (5%), baekchul (5%), phalanges (10%) (7%), short skin (3%), talc (5%), and earth and sand (5%).
실험예 1Experimental Example 1
<본 발명의 조성물이 정상 새끼쥐에 미치는 혈당강하효과><Glucose lowering effect of the composition of the present invention on normal mice>
체중이 20±2g의 흰 새끼쥐 40마리를 1조에 10마리씩 4조로 나누어 넣고, 약물이 투여되지 않은 정상조에는 당량의 생리식염수를 복강에 투여하고, 약물조에는 글리벤클라마이드(Glibenclamide)를 새끼쥐 복강에 5㎎/㎏을 투여하고, 본 발명 조성물 투여조에는 본 발명의 조성물 2g/㎏과 1g/㎏을 각각 새끼쥐 복강에 투여하였다. 모두 15일 동안 투여하였다. 약을 투여하기 전과 약을 투여한 지 15일 후, 쥐꼬리에서 0.05㎖ 정도의 혈액을 채취하여 미국산 JD2DGA7CC형 미량혈당 측정기를 이용하여 공복시의 혈당치를 측정하였다. 측정된 결과는 표1에 나타내었다.40 rats weighing 20 ± 2 g are divided into 4 groups of 10 rats per 1 group. For normal tanks without drug, an equivalent amount of physiological saline is administered to the abdominal cavity, and the drug tank is administered with glycenclamide (Glibenclamide) 5 mg / kg was administered, and 2 g / kg and 1 g / kg of the composition of the present invention were administered to the intraperitoneal rats, respectively. All were administered for 15 days. Before administration and 15 days after administration, approximately 0.05 ml of blood was collected from the rat tail and the fasting blood glucose level was measured using a US JD2DGA7CC microglucometer. The measured results are shown in Table 1.
※ mmol/L → ㎎/㎗ : × 17.90 ()안의 숫자는 혈당 저하율(%)※ mmol / L → mg / dl: × 17.90
※ 정상조와 비교 : * P<0.05※ Comparison with normal: * P <0.05
상기 표1에 기재된 결과로 부터 알 수 있는 바와 같이, 본 발명의 조성물은 기존에 이미 당뇨병 치료제로서의 효능이 입증되어 있는 글리벤클라마이드와 마찬가지로 정상 새끼쥐에서 혈당강하효과를 나타낸다.As can be seen from the results described in Table 1, the composition of the present invention exhibits a hypoglycemic effect in normal pups as well as glybenclamide, which has already been proven to be effective as an antidiabetic agent.
실험예 2Experimental Example 2
<본 발명의 조성물이 알록손 투여된 당뇨병 새끼쥐에게 미치는 혈당강하 효과>Hypoglycemic Effect of the Composition of the Present Invention on Alloxone-Induced Diabetic Rats
체중이 20±2g의 흰 새끼쥐 암수를 함께 실험하였다. 실험 전에 12시간 동안 금식시키고, 정상조를 제외한 각조에 신선하게 배합하여 만든 2%의 알록손용액 200㎎/㎏을 복강에 주사하였다. 48시간 후, 12시간 금식시킨 동물의 공복혈당뇨를 측정하여 16.67mmol/L를 초과한 당뇨병의 새끼쥐 40마리를 1조에 10마리씩 4조로 나누었다. 정상조 10마리는 알록손을 투여하지 않았다. 정상조와 모형조에는 당량의 생리식염수를 복강에 투여하고, 약물조에는 글리벤클라마이드를 새끼쥐 복강에 5㎎/㎏을 투여하고, 본 발명의 조성물 투여조에는 본 발명의 조성물 2g/㎏과 1g/㎏을 각각 새끼쥐 복강에 투여하였다. 모두 15일 동안 투여하였다. 약을 투여하기 전과 약을 투여한 지 15일 후, 쥐꼬리에서 0.05㎖ 정도의 혈액을 채취하여 미국산 JD2DGA7CC형 미량혈당 측정기를 이용하여 공복시의 혈당치를 측정하였다. 측정된 결과는 표2에 나타내었다.Male and female rats weighing 20 ± 2 g were tested together. Fasting for 12 hours before the experiment, and 200 mg / kg of 2% alloxone solution prepared by mixing fresh in each tank except the normal tank intraperitoneally. After 48 hours, fasting blood glucose levels of animals fasted for 12 hours were measured, and 40 rats with diabetes exceeding 16.67 mmol / L were divided into 4 groups of 10 rats. Ten normal rats did not receive alloxone. Normal and model tanks were administered with an equivalent amount of physiological saline to the abdominal cavity, and drug tanks were administered 5 mg / kg to the rat abdominal cavity, and to the composition administration tank of the present invention, 2 g / kg and 1 g / kg of the composition of the present invention. Were administered to the rat abdominal cavity, respectively. All were administered for 15 days. Before administration and 15 days after administration, approximately 0.05 ml of blood was collected from the rat tail and the fasting blood glucose level was measured using a US JD2DGA7CC microglucometer. The measured results are shown in Table 2.
※ mmol/L → ㎎/㎗ : × 17.90 ()안의 숫자는 혈당 저하율(%)※ mmol / L → mg / dl: × 17.90
※ 모형조와 비교 : *** P<0.001※ Comparison with model: *** P <0.001
상기 표2에 기재된 결과로 부터, 본 발명의 조성물은 기존에 이미 당뇨병 치료제로서의 효능이 입증되어 있는 글리벤클라마이드와 마찬가지로 알록손 투여된 당뇨병 새끼쥐에서 혈당을 현저하게 저하시키는 것을 알 수 있다.From the results described in Table 2, it can be seen that the composition of the present invention significantly lowers blood sugar levels in alloxone-administered diabetic rats like glybenclamide, which has already been proven to be effective as an antidiabetic agent.
알록손이 유리기 OH를 생성하면, 담낭이 지나치게 산화되어 인슐린 베타 세포가 상하게 되므로써 당뇨병을 유발하게 되는데, 본 발명의 조성물은 이와같은 베타세포에 손상 입히는 작용을 감소시켜 인슐린을 정상으로 회복시킨다.When aloxone produces free radical OH, the gallbladder is excessively oxidized, causing insulin beta cells to be damaged, leading to diabetes. The composition of the present invention reduces the action of damaging such beta cells to restore insulin to normal.
실험예 3Experimental Example 3
<본 발명의 조성물이 아드레날린 투여된 큰쥐에게 미치는 혈당강하효과><Glucose lowering effect of the composition of the present invention on rats receiving adrenaline>
체중이 180±20g의 위스터 숫컷 큰쥐 50마리를 1조에 10마리씩 5조로 나누었다. 실험 전에 24시간 동안 금식시키고, 정상조를 제외한 각조 쥐의 피하에 0.1% 아드레날린 0.2㎖/㎏을 주사하고, 정상조의 피하에 같은 양의 생리식염수를 주사하고, 각조의 피하에 같은 양의 생리식염수를 주사한 다음 바로 다른 약물을 복강에 투여하였다. 90분, 130분 후에 각각 큰쥐의 꼬리에서 모두 0.05㎖정도의 혈액을 채취하여 미국산 JD2DGA7CC형 미량혈당 측정기를 이용하여 혈당치를 측정하고, 각 조별로 비교하였다. 측정된 결과는 표3에 나타내었다.Fifty male Wister male rats weighing 180 ± 20 g were divided into 5 groups of 10 animals per group. Fast 24 hours before the experiment, inject 0.2 ml / kg of 0.1% adrenaline into the subcutaneous rats except normal rats, inject the same amount of saline into the subcutaneous rats, and the same amount of saline into the subcutaneous rats. Immediately after injection, another drug was administered intraperitoneally. After 90 minutes and 130 minutes, about 0.05ml of blood was collected from the tails of large mice, and blood glucose levels were measured using a US-based JD2DGA7CC microglucometer. The measured results are shown in Table 3.
※ mmol/L → ㎎/㎗ : × 17.90 ()안의 숫자는 혈당 저하율(%)※ mmol / L → mg / dl: × 17.90
※ 모형조와 비교 : * P<0.05, ** P<0.01, *** P<0.001※ Comparison with model: * P <0.05, ** P <0.01, *** P <0.001
상기 표3에 기재된 결과로부터, 본 발명의 조성물은 정상 새끼쥐의 혈당은 거의 저하시키지 않으면서, 아드레날린 당뇨병 큰쥐의 혈당은 저하시키는 것을 알 수 있다.From the results shown in Table 3, it can be seen that the composition of the present invention lowers the blood sugar of the adrenaline diabetic rats while almost reducing the blood sugar of the normal pups.
실험예 4Experimental Example 4
<급성독성 실험>Acute Toxicity Test
체중이 20±2g인 흰색 새끼쥐 30마리를 골라 암수 구분 없이 새끼쥐의 복강에 각각 본 발명의 조성물 5g/㎖(최대농도) 1㎖/20g(최대용량)을 24시간 동안 모두 3차례 투여하고, 10일 동안 관찰한 결과 모두 생존하였으며, 이상 반응은 없었다. 흰 새끼쥐의 최대 내구량 배수를 계산하면 다음과 같다.Thirty white mice weighing 20 ± 2 g were selected, and 5 g / ml (maximum concentration) of the composition of the present invention were administered three times for 24 hours in each of the abdominal cavity of the male and female without discrimination. , And all of them survived for 10 days, and there was no adverse reaction. The maximum endurance multiples of white pups are calculated as follows.
위와 같은 실험결과에 따르면 본 발명의 조성물이 흰 새끼쥐의 복강에 한 번 주입되는 최대 내구량은 250g/㎏(5g/20g)으로, 최대 내구량 배수는 347.2배에 달한다. 또한 하루에 주입되는 최대 내구량은 750g/㎏(15g/20g)으로, 최대 내구량 배수는 1041.7배이다. 750g/㎏/일을 투여하는 것은 체중 50㎏으로 환산시 본 발명의 조성물을 1일에 3.75㎏이상 투여하는 효과를 나타내므로 본 발명의 조성물은 실질적으로 독성이 거의 없다는 것을 알 수 있다.According to the above experimental results, the composition of the present invention is injected once into the abdominal cavity of a white mouse, the maximum endurance is 250g / ㎏ (5g / 20g), the maximum endurance amount reaches 347.2 times. In addition, the maximum endurance injected per day is 750g / kg (15g / 20g), the maximum endurance multiple is 1041.7 times. Administering 750g / kg / day shows the effect of administering more than 3.75kg of the composition of the present invention in terms of 50kg body weight per day it can be seen that the composition of the present invention is substantially non-toxic.
상기한 바와 같이 본 발명의 조성물은 위모의 옥살로아세트산 성분에 여러가지 생약성분을 배합하여 위모의 단독 사용에 따른 부작용을 방지함은 물론 당뇨병에 의해 야기될 수 있는 각종 증상을 모두 적절히 치료할 수 있어 음허성 당뇨병 즉 제2형 당뇨병에 탁월한 치료 효과가 있다.As described above, the composition of the present invention includes various herbal ingredients in the oxaloacetic acid component of the stomach to prevent side effects due to the use of the stomach alone as well as to properly treat all the various symptoms that may be caused by diabetes. There is an excellent therapeutic effect on ischemic diabetes, namely type 2 diabetes.
또한 본 발명의 조성물은 독성이 거의 없으므로 혈당강하용 건강식품에도 적용이 가능하다.In addition, the composition of the present invention is almost non-toxic and can be applied to a blood sugar-lowering health food.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000044392A KR100364390B1 (en) | 2000-07-31 | 2000-07-31 | Compositions for the treatment of diabetes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000044392A KR100364390B1 (en) | 2000-07-31 | 2000-07-31 | Compositions for the treatment of diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020011015A KR20020011015A (en) | 2002-02-07 |
KR100364390B1 true KR100364390B1 (en) | 2002-12-12 |
Family
ID=19681082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020000044392A KR100364390B1 (en) | 2000-07-31 | 2000-07-31 | Compositions for the treatment of diabetes |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100364390B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101361846B1 (en) | 2013-02-14 | 2014-02-13 | 강원대학교산학협력단 | Atural plant composition for modulate enzyme mrna relate to glucose metabolism in cell |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040005070A (en) * | 2002-07-08 | 2004-01-16 | 김영일 | Composite of health ancillary food |
EP1974736A1 (en) * | 2007-03-23 | 2008-10-01 | Phyto Health Pharma B.V. | A composition for the treatment of diabetes mellitus |
EP1974737A1 (en) * | 2007-03-23 | 2008-10-01 | Phyto Health Pharma B.V. | Composition for the treatment of diabetes mellitus and metabolic syndrome |
WO2010032267A2 (en) | 2008-09-22 | 2010-03-25 | Innoveda Biological Solutions (P) Ltd. | A herbal fromulation for prevention and treatment of diabetes and associated complications |
GB2487616A (en) * | 2011-01-25 | 2012-08-01 | qi ling Wang | Plant-based drug for diabetes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR920003620A (en) * | 1990-07-19 | 1992-02-29 | 정용문 | Stepping motor driving circuit and its driving method |
KR19980033798A (en) * | 1996-11-01 | 1998-08-05 | 김상조 | Pharmaceutical composition for the treatment of diabetes |
KR101212889B1 (en) * | 2010-10-01 | 2012-12-14 | 하이디스 테크놀로지 주식회사 | Cassette for loading Glasses |
KR101243006B1 (en) * | 2010-12-28 | 2013-03-12 | 주식회사 포스코 | Aluminium plated ferritic stainless steel welding method |
-
2000
- 2000-07-31 KR KR1020000044392A patent/KR100364390B1/en not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR920003620A (en) * | 1990-07-19 | 1992-02-29 | 정용문 | Stepping motor driving circuit and its driving method |
KR19980033798A (en) * | 1996-11-01 | 1998-08-05 | 김상조 | Pharmaceutical composition for the treatment of diabetes |
KR101212889B1 (en) * | 2010-10-01 | 2012-12-14 | 하이디스 테크놀로지 주식회사 | Cassette for loading Glasses |
KR101243006B1 (en) * | 2010-12-28 | 2013-03-12 | 주식회사 포스코 | Aluminium plated ferritic stainless steel welding method |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101361846B1 (en) | 2013-02-14 | 2014-02-13 | 강원대학교산학협력단 | Atural plant composition for modulate enzyme mrna relate to glucose metabolism in cell |
Also Published As
Publication number | Publication date |
---|---|
KR20020011015A (en) | 2002-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mukhtar et al. | A modern overview on diabetes mellitus: a chronic endocrine disorder | |
KR100195886B1 (en) | Pharmaceutical composition for treating diabetes mellitus | |
Said et al. | Maintaining a physiological blood glucose level with ‘glucolevel’, a combination of four anti‐diabetes plants used in the traditional Arab herbal medicine | |
Das et al. | Okra and its various applications in drug delivery, food technology, health care and pharmacological aspects-a review | |
CN101987169A (en) | Composition comprising an extract of herbal combination thereof for preventing and treating diabetes mellitus | |
CN107080250A (en) | A kind of composition of auxiliary hyperglycemic, beverage and preparation method thereof | |
JPH08127538A (en) | Antidiabetic agent | |
CN113616688B (en) | Anserine composition for repairing kidney injury and application thereof | |
CN103653148B (en) | Guava leaf liquid beverage | |
CN107006856A (en) | One kind enhancing endurance, raising anti anoxia tolerance nutritional agents and preparation method thereof | |
KR100364390B1 (en) | Compositions for the treatment of diabetes | |
KR100591539B1 (en) | Dietary supplement composition | |
KR100831621B1 (en) | The plant extracts composition for the blood glucose reducing action | |
EP2567704A1 (en) | Traditional chinese medicine composition for treating diabetes and preparation method thereof | |
KR100952188B1 (en) | Health Food For The Descent Of HbA1c | |
KR101989739B1 (en) | Composition for preventing or treating diabetes mellitus comprising Rorippa globosa extracts | |
CN1814214A (en) | Chinese medicine composition for treating body thin and delicate coustitution, and preparing method | |
CN101336965A (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
US20140127333A1 (en) | Preparation, process and a regenerative method and technique for prevention, treatment and glycemic control of diabetes mellitus | |
CN101152223A (en) | Use of poplar leaf phenols extract in treating cardiovascular disease and extracting method thereof | |
KR20040003888A (en) | Composition of crude drug, method of preparing the same and pharmaceutical preparation including the same for curing diabetes mellitus | |
KR20070025066A (en) | Herbal composition for treatment and prevention of diabetes and diabetic complications | |
KR20090126469A (en) | The herb extract composition for the blood glucose reducing action | |
CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
KR0179088B1 (en) | Composition containing rhodiola sachalinesis extract for prophylaxis and treatment of diabetes mellitus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20051118 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |